- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Location Directory
Clinical trials in Pittsburgh, Pennsylvania
This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10636
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 685–696 of 10,636 matching trials in Pittsburgh, PA.
Live ClinicalTrials.gov results.
Institutions in Pittsburgh
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Irvine, California • Orange, California • Gainesville, Florida + 14 more
- Conditions
- Peanut Allergy
- Interventions
- DBV712 250 mcg
- Biological
- Lead sponsor
- DBV Technologies
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- BodyGuardian
- Device
- Lead sponsor
- Heart Rhythm Clinical and Research Solutions, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Delray Beach, Florida • Miami, Florida • Iowa City, Iowa + 2 more
- Conditions
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Interventions
- Ivosidenib 500mg, Placebo
- Drug
- Lead sponsor
- Servier Bio-Innovation LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more
- Conditions
- COPD
- Interventions
- Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo
- Biological · Other
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 94
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Peoria, Arizona + 82 more
- Conditions
- Community Mobility of Older Adults, Locomotor Adaptability, Gait Automaticity
- Interventions
- Split-belt walking, Multiple transitions between split-belt and tied-belt walking
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Interventions
- Tirabrutinib, Rituximab, Temozolomide
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 19 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, Venetoclax
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 136
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more
- Conditions
- Breast Cancer
- Interventions
- ctDNA MRD test
- Diagnostic Test
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 56
- States / cities
- Anchorage, Alaska • Palo Alto, California • Torrance, California + 48 more
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 365 Days
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
- Conditions
- Overactive Bladder (OAB), Urinary Urgency, Urinary Urge Incontinence (UUI), Nocturia, Urinary Frequency
- Interventions
- RiSolve App, AUGS Patient Handouts
- Device · Behavioral
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 22 Years and older · Female only
- Enrollment
- 596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 7 more